



02-12-07

1615/4

Docket No.: 2001377.122US1
Express Mail No. EV 842150688 US
Deposited February 9, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gregor CEVC	Conf. No.:	9461
Application No.:	09/555,986	Art Unit:	1615
Filed:	August 17, 2000	Examiner:	G. S. Kishore
Title:	METHOD FOR DEVELOPING, TESTING AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, the Examiner's attention is invited to the attached Form PTO/SB/08, listing references DA-DZ, DAA-DAS, EA-ET, and FA-FG, and to the attached copies of references EA-ET and FA-FG. Also submitted herewith is a copy of a preliminary amendment that was filed in connection with U.S. Application No. 11/481,804, which is a continuation of U.S. Application No. 09/621,574. It is respectfully requested that the Examiner make the attached preliminary amendment and references of record by reviewing them and initialing and returning a copy of the enclosed Form PTO/SB/08 with the next Patent Office communication.

A fee of \$180.00 is believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. The Commissioner is authorized to debit any necessary fee from or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Matthew E. Langer
Reg. No. 36,343

Dated: February 9, 2007

Matthew E. Langer
Registration No.: 36,343

Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 10022
(212) 230-8800 (telephone)
(212) 230-8888 (facsimile)

02/12/2007 HBLANCO 00000001 000219 09555986
01 FC:1886 180.00 DA



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/555,986	
			Filing Date	August 17, 2000	
			First Named Inventor	Gregor CEVC	
			Art Unit	1615	
			Examiner Name	G. S. Kishore	
Sheet	1	of	3	Attorney Docket Number	2001377.122-US1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	DA	US-4,666,747	05-19-1987	Quinn et al.	
	DB	US-4,746,509	05-24-1988	Haggiage et al.	
	DC	US-4,783,450	11-08-1988	Fawzi et al.	
	DD	US-5,104,661	04-14-1992	Lau	
	DE	US-5,145,684	09-08-1992	Liversidge et al.	
	DF	US-5,154,930	10-13-1992	Popescu et al.	
	DG	US-5,498,418	3-12-1996	Beutner, et al.	
	DH	US-5,510,118	04-23-1996	Bosch et al.	
	DI	US-5,552,160	09-03-1996	Liversidge et al.	
	DJ	US-5,654,337	08-05-1997	Roentsch et al.	
	DK	US-5,716,638	02-10-1998	Touitou et al.	
	DL	US-5,837,289	11-17-1998	Grasela et al.	
	DM	US-5,858,330	01-12-1999	Boltri et al.	
	DN	US-5,874,422	02-23-1999	Krause et al.	
	DO	US-5,891,472	04-06-1999	Russell	
	DP	US-5,985,860	11-16-1999	Toppo	
	DQ	US-6,028,066	02-22-2000	Unger	
	DR	US-6,045,827	04-04-2000	Russell	
	DS	US-6,069,172	05-30-2000	Bertini et al.	
	DT	US-6,083,996	07-04-2000	Buyuktimkin et al.	
	DU	US-6,165,500	12-26-2000	Cevc et al.	
	DV	US-6,193,996	02-27-2001	Effing et al.	
	DW	US-6,200,598	03-13-2001	Needham	
	DX	US-6,214,386	04-10-2001	Santus et al.	
	DY	US-20010012849-A1	08-09-2001	Wechter	
	DZ	US-6,294,192	09-25-2001	Patel et al.	
	DAA	US-6,303,141	10-16-2001	Fischer, et al.	
	DAB	US-20020003179-A1	01-10-2002	Verhoff et al.	
	DAC	US-20020012680-A1	01-31-2002	Patel et al.	
	DAD	US-20020037877-A1	03-28-2002	Singh	
	DAE	US-20020048596-A1	04-25-2002	CEVC	
	DAF	US-6,387,383	05-14-2002	Dow et al.	
	DAG	US-20020106345-A1	08-08-2002	Uhrich et al.	
	DAH	US-20020119188-A1	08-29-2002	Niemiec et al.	
	DAI	US-6,448,296	09-10-2002	Yasueda et al.	
	DAJ	US-6,451,339	09-17-2002	Patel et al.	
	DAK	US-20020147238-A1	10-10-2002	Jerussi et al.	
	DAL	US-6,577,880	06-10-2003	Ishida et al.	
	DAM	US-6,582,724	06-24-2003	Hsu et al.	
	DAN	US-6,586,000	07-01-2003	Luo et al.	
	DAO	US-6,645,520	11-11-2003	Hsu et al.	
	DAP	US-6,726,598	04-27-2004	Jarvis et al.	
	DAQ	US-6,797,276	09-28-2004	Glenn et al.	
	DAR	US-6,835,392	12-28-2004	Hsu et al.	
	DAS	US-6,868,686	03-22-2005	Ueda et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

6045805

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/555,986
				Filing Date	August 17, 2000
				First Named Inventor	Gregor CEVC
				Art Unit	1615
				Examiner Name	G. S. Kishore
Sheet	2	of	3	Attorney Docket Number	2001377.122-US1

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code-Number-Kind Code (if known)	MM-DD-YYYY			
	EA	EP-0355095	08-04-1993	THE LIPOSOME COMPANY, INC.		
	EB	CA-2160775	11-24-1994	MERCK PATENT GMBH, et al		
	EC	EP-0382716	01-28-1998	WARNER-LAMBERT CO.		
	ED	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		
	EE	WO-99/22703	05-14-1999	LURIDENT LTD.		
	EF	WO-00/00597	01-06-2000	THE UNIVERSITY OF MANITOBA		
	EG	WO-00/12060	03-09-2000	IDEA INNOVATIVE DERMAL APPLICATIONEN GMBH		
	EH	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
	EI	EP-0995435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.		
	EJ	WO-00/24377	05-04-2000	IDEA INNOVATIVE APPLICATIONEN GMBH		
	EK	WO-00/25822	05-11-2000	John C. Grasela, et al.		
	EL	WO-00/38653	07-06-2000	IDEA INNOVATIVE DERMAL APPLICATIONEN GMBH		
	EM	WO-00/44350	08-03-2000	IDEA AG		
	EN	WO-00/50007	08-31-2000	LIPOCINE, INC.		
	EO	WO-01/01963	01-11-2001	IDEA AG		
	EP	WO-02/07767	01-31-2002	ALCON UNIVERSAL LTD.		
	EQ	WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES		
	ER	WO-01/12155	02-22-2001	LIPOCINE, INC.		
	ES	EP-1031347	04-17-2002	IDEA AG		
	ET	EP-1031346	05-02-2002	IDEA AG		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/555,986
				Filing Date	August 17, 2000
				First Named Inventor	Gregor CEVC
				Art Unit	1615
				Examiner Name	G. S. Kishore
				Attorney Docket Number	2001377.122-US1
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	FA	Calpena, A. et al., "Influence of the Formulation on the In Vitro Transdermal Penetration of Sodium Diclofenac," <i>Arzneim.-Forsch./Drug Res.</i> 49(II), 1012-1017 (1999).	
	FB	Carafa, M. et al. "Lidocaine-loaded Non-ionic Surfactant Vesicles: Characterization and In Vitro Permeation Studies," <i>International Journal of Pharmaceuticals</i> 231:21-32. (2002)	
	FC	Cevc, G. et al. "Newly, Highly Efficient Formulation of Diclofenac for the Topical, Transdermal Administration in Ultradeformable Drug Carriers, Transfersomes," <i>Biochimica et Biophysica Acta</i> 1514:191-205. (2001)	
	FD	Friedrich, I. et al., "Physicochemical Characterization of a Reverse Micellar Solution after Loading with Different Drugs," <i>Pharmazie</i> 55(10):755-758. (2000)	
	FE	Gesztes, A. et al., "Topical Anesthesia of the Skin by Liposome-Encapsulated Tetracaine," <i>Anesth Analg</i> , 67:1079-1081. (1988)	
	FF	Swenson, E. Scott and William J. Curatolo. "Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity." <i>Adv. Drug Delivery Reviews</i> , 8:39-92. (1992).	
	FG	Valenta, C. et al., "Evaluation of Novel Soya-lecithin Formulations for Dermal use containing Ketoprofen as a Model Drug," <i>Journal of Controlled Release</i> 63:165-173. (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--